Regulatory November 30, 2023

Lipidor changes Certified Adviser to Carnegie Investment Bank AB (publ)

STOCKHOLM, Sweden, 30th November 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).

Lipidor has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on 30th November 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

Publication

The information was provided for publication by Lipidor’s CEO on 30th November 2023 at 10.00 am (CET).

For more information, please contact:

Ola Holmlund, CEO
Telephone: +46 (0) 72 50 70 369
Email: ola.holmlund@lipidor.se

The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Lipidor AB
Lipidor AB (Nasdaq First North Growth Market: LIPI) (www.lipidor.se) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor’s priority project is AKP02G2, which focusses on psoriasis.

Attachments
Lipidor changes Certified Adviser to Carnegie Investment Bank AB (publ)

Lipidor changes Certified Adviser to Carnegie Investment Bank AB (publ)